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Abstract
Lipopolysaccharide (LPS) elicits a strong immune response, which leads to the release of inflammatory cytokines. Increased
cytokine production has been shown to impair insulin-mediated glucose disposal. LPS can alter other factors, such as
muscle blood flow and insulin signaling in the myocyte,that can influence glucose disposal. We hypothesize that LPS
induced impairments in cardiovascular function contribute to the associated impairments in insulin action in vivo. Male
wild-type C57BL/6J mice had a catheter implanted in the jugular vein for infusions and the carotid artery for sampling 5
days prior to the hyperinsulinemic-euglycemic clamp. Mice were treated with vehicle, low-(1 ug/gBW) or high-dose (10 ug/
gBW) LPS 4 hours prior to the clamp. Muscle glucose uptake (MGU) was assessed using [2-
14C] deoxyglucose. While both
low- and high-dose LPS inhibited insulin-stimulated MGU compared to vehicle-treated mice, the impairment was more
significant with the high-dose treatment (,25% in soleus and ,70% in both gastrocnemius and vastus lateralis).
Interestingly, insulin signaling through the PI3-kinase pathway in the muscle was not affected by this treatment suggesting
that the decrease in MGU is not directly due to impairments in muscle insulin action. Echocardiography demonstrated that
high-dose LPS treatment significantly decreased stroke volume (,30%), heart rate (,35%), and cardiac output (,50%).
These observations were not seen with vehicle or low-dose LPS treatment. High-dose LPS treatment also significantly
decreased muscle blood flow (,70%) and whole body oxygen consumption (,50%). Thus, in vivo acute endotoxemia does
not impair insulin signaling through the PI3-kinase pathway in skeletal muscle and decreased tissue blood flow likely plays a
central role in the impairment of glucose uptake in the muscle.
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Introduction
Sepsis has been defined as ‘‘the systemic inflammatory response
to infection’’ [1]. It is the second leading cause of death in non-
coronary intensive-care unit (ICU) patients and a major cause of
morbidity and mortality. During sepsis, lipopolysaccharide (LPS),
which is derived from the cell wall of gram-negative bacteria, can
induce the expression of inflammatory mediators and cytokines
such as TNF-a, interleukin-6 (IL-6), interleukin-1b (IL-1b), and
interleukin-10 (IL-10), as well as lead to the release of nitric oxide
(NO). Common side effects in response to sepsis are hyperglycemia
and severe insulin resistance. This is in part due to the role that the
immune response plays in the regulation of skeletal muscle glucose
uptake (MGU). Skeletal muscle comprises the bulk of insulin-
sensitive tissue in the body and is an important site for glucose
disposal. Insulin augments MGU by not only regulating insulin-
stimulated GLUT4 translocation and subsequent glucose phos-
phorylation in the muscle but by also enhancing tissue blood flow
[2,3,4,5].
Mediators of the inflammatory response have been shown to
impair muscle insulin signaling and blood flow, however little work
has been done to examine how these factors interact with one
another in vivo. Youd et al. has shown that in vivo a 3 hour infusion
of TNF-a into anesthetized rats inhibited insulin-stimulated
microvascular recruitment and lead to decreased insulin-stimulat-
ed hind-leg glucose uptake. However, insulin signaling was not
measured in this study [6]. While TNF-a has been shown to
impair the vasodilator effects of insulin in skeletal muscle resistance
arteries through impairments of insulin activation of AKT in rats
[7] and impair insulin signaling and insulin-stimulated glucose
uptake in muscle [8], this work was done either ex vivo or in
cultured cells. In vivo Fan et al. found that LPS lead to whole body
insulin resistance in rats and impaired insulin signaling [9]. Yet a
recent in vivo study utilizing a hyperinsulinemic-euglycemic clamp
in mice was unable to detect an impairment in insulin action
following an i.p. LPS injection [10]. Therefore it is unclear how
much of the impairments seen with acute inflammatory stress are
signaling- and/or cardiovascular–mediated. Interestingly the
majority of the work has been done in rats, with limited and
apparently different responses in mice.
While any number of factors can contribute to inhibition of
insulin-stimulated glucose uptake in the presence of an LPS
challenge, there has been little work to examine the relationship
between the LPS induced inflammatory response and cardiac
dysfunction, insulin signaling, and decreased muscle glucose
delivery in vivo. There are vascular as well as metabolic events
occurring in vivo that can affect glucose metabolism. The aim of the
current study was to examine the relationship between cardiovas-
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delivery when mice are challenged with LPS in vivo utilizing several
modifications to more specifically examine the physiological effects
on skeletal muscle. We hypothesized that if LPS is accompanied by
alterations in the cardiovascular system, alterations in tissue blood
flow as opposed to insulin signaling are major contributors to the
impaired muscle glucose uptake.
Methods
Animal Care and Husbandry
All procedures were performed on male wild-type (WT)
C57BL/6J background (Jackson Laboratories, Bar Harbor, ME).
At three weeks of age, mice were separated by gender and
maintained in micro-isolator cages on a 12-h light/dark cycle with
free access to food and water. All experiments were performed in
mice at ,3 months of age. The Vanderbilt University Institutional
Animal Care and Use Committee approved all procedures
performed.
Surgical Procedures
The surgical procedures utilized to implant chronic catheters
have been described previously [11,12]. Briefly, mice were
anesthetized with isoflurane. The left common carotid artery
and right jugular vein were catheterized for sampling and infusing,
respectively. The free ends of the catheters were tunneled under
the skin to the back of the neck where the loose ends of the
catheters were attached via stainless steel connectors to tubing
made of Micro-Renathane (0.033 in OD). The tubing was
exteriorized and sealed with stainless steel plugs. Animals were
individually housed after surgery and body weight was recorded
daily.
In Vivo Metabolic Experiments
All metabolic experiments were performed following a ,5-day
postoperative recovery period. Mice were not used in experiments
unless their body weight was within 10% of their body weight
prior to catheter implantation. For metabolic studies, conscious,
unrestrained mice were placed in an ,1-L plastic container lined
with bedding and fasted at 7:00 am (t=2300 min). The mice
were immediately connected to a Dual Channel Stainless Steel
Swivel (Instech Laboratories, Plymouth Meeting, PA) to allow
simultaneous jugular vein infusion and sampling of arterial blood.
Mice were not handled and were allowed to move freely to
eliminate stress. Prior to vehicle or endotoxin injection
(t=2240 min) a blood sample (60 ml) was drawn for measurement
of blood glucose and plasma cytokine levels. Mice then received a
bolus of vehicle or E. coli endotoxin (LPS; 0111:B4)
(Lot#129K4025, Sigma-Aldrich, St. Louis, MO) at a dose of
either 1 ug/gBW (low-dose) or 10 ug/gBW (high-dose) into the
jugular vein catheter. Five mCi bolus of [3-
3H]-D-glucose was
given into the jugular vein 2 h after the mice received the bolus
(t=2120 min) followed by a constant infusion at a rate of
0.05 mCi/min. Following a 2 h equilibrium period at t=0 min
(i.e. 4 h after the bolus and a 5 h fast) a baseline arterial blood
sample (200 ml) was drawn for measurement of blood glucose,
[3-
3H]-D-glucose, hematocrit, plasma insulin, and plasma cyto-
kine levels. Red blood cells from a donor mouse on a C57Bl/6J
background were washed with and reconstituted in an equal
volume of 0.9% heparinized saline (hematocrit ,50%) and infused
at a rate of 4 ml/min for the duration of the study to minimize falls
in the hematocrit (Figure 1).
A hyperinsulinemic-euglycemic (120 mg/dl) clamp was used to
assess insulin action in three groups: vehicle+insulin (4.0 mU/kg/
min, n=8); low-dose LPS+insulin (2.0 mU/kg/min, n=8); or
high-dose LPS+insulin (2.5 mU/kg/min, n=10). A lower dose of
insulin was used in the LPS groups to attempt to match arterial
insulin concentrations as initial studies indicated LPS impaired
insulin clearance. Arterial blood samples (10 ml) were taken every
ten minutes to determine blood glucose levels. At t=70, 80, 90
and 100 min, blood samples (50 ml) were taken to determine
[3-
3H]-D-glucose. At t=100 min, a 13 mCi bolus of 2-deoxy [
14C]
glucose ([2-
14C]DG) was administered into the jugular vein
catheter. At t=102, 105, 110, 115, and 125 min arterial blood
(20 ml) was sampled to determine blood glucose, plasma [3-
3H]-D-
glucose and [2-
14C]DG. At t=125 min (,6 h after the vehicle or
LPS bolus), a final arterial blood sample (200 ml) was taken to
assess circulating hormones and plasma [2-
14C]DG. The mice
were then anesthetized. The soleus, gastrocnemius, superficial
vastus lateralis (SVL), liver, heart, and brain were excised,
immediately frozen in liquid nitrogen, and stored at 270uC until
future tissue analysis. Basal plasma glucose levels and tissue glucose
uptake was assessed in three additional groups: vehicle+saline
infusion (n=9), low-dose LPS+saline infusion (n=6), and high-
dose LPS+saline infusion (n=8). Comparison of these studies to
the insulin clamp experiments permits insulin-independent effects
of LPS to be defined.
In a separate group of studies the effects of LPS on the acute
activation of insulin signaling was examined. Mice were placed on
a 5 h fast (t=2300 min) and received either an I.V. bolus of
vehicle or high-dose LPS 1 h after the fast began (t=2240 min).
Four h later (t=0 min), mice received an I.V. bolus of insulin
(10 U/kg body weight). At t=10 min, the mice were anesthetized.
The gastrocnemius muscle and liver were excised, immediately
frozen in liquid nitrogen, and stored at 270uC until future tissue
analysis.
Plasma and muscle sample analysis
Immunoreactive insulin was assayed using a Linco Rat
Radioimmunoassay kit (Linco Research, Inc., St. Charles, MO).
Cytokines were analyzed using multiplexing Luminex xMAP
technology (Luminex, Austin, TX). Plasma samples were prepared
using mouse cytokine/chemokine Lincoplex kit (Linco Research,
St. Charles, MO). To measure [3-
3H]-D-glucose plasma samples
were deproteinized with barium hydroxide (Ba(OH)2) and zinc
sulfate (ZnSO4), dried, and radioactivity was determined using
liquid scintillation counting. Excised soleus, gastrocnemius, SVL,
heart, and brain were deproteinized with perchloric acid and then
neutralized to a pH of ,7.5. A portion of the sample was counted
([2-
14C]DG and [2-
14C]DG-G-phosphate ([2-
14C]DGP) and a
portion was treated with Ba(OH)2 and ZnSO4 and the supernatant
was counted ([2-
14C]DG). Both [2-
14C]DG and [2-
14C]DG-
phosphate ([2-
14C]DGP) radioactivity levels were determined
using liquid scintillation counting.
Calculations
Glucose flux rates were assessed using non-steady state
equations assuming a volume of distribution (130 ml/kg). Tissue-
specific clearance (Kg) of [2-
14C]DG and an index of glucose
uptake (Rg) was calculated as previously described [13]:
Kg~
½2{14C DGPtissue
AUC½2{14C DGplasma
Rg~Kg|½glucose plasma
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14C]DGPtissue is the [2-
14C]DGP radioactivity (dpm/g)
in the tissue, AUC [2-
14C]DGplasma is the area under the plasma
[2-
14C]DG disappearance curve (dpm/mL/min), and [glucose]-
plasma is the average blood glucose (mg/ml) during the experimental
period (t=102–125 min). Data are presented as mean 6 SEM
and the significance level was set at p,0.05.
Blood Pressure
Mean arterial blood pressure (MAP) was measured in conscious
mice utilizing a Micro-Med, Inc. Blood Pressure Analyzer
(Louisville, KY). Baseline blood pressure and heart rate measure-
ments were taken from the carotid artery prior to the LPS
injection (t=2240 min) and measurements were repeated 4 h
post-LPS injection (t=0 min).
Blood Flow
A separate group of mice that were treated with vehicle, low- or
high-dose LPS received an infusion of para-amino hippuric acid
(PAH). PAH clearance was used to estimate renal blood flow. At
t=2240 min animals received a bolus of either vehicle, low- or
high-dose LPS. At t=2120 min, animals received a constant
infusion of PAH dissolved in saline into the jugular vein at a rate of
24 mg/g/min. Plasma samples were taken at t=2120, 0 (4 h
following a bolus of VEH or LPS), 60, and 120 min. The plasma
was diluted 1:5 in Ba(OH)2 and ZnSO4, centrifuged at
13,000 rpm for 5 min, and the supernatant was diluted 1:6 in
ddH2O. The samples were then diluted 1:6 in the PAH reagent
(5 g dimethylaminobenzaaldehyde, 300 mL 95% ethanol, 20 mL
2N HCL, and ddH2O to a final volume of 500 mL) and the
absorbance of PAH was determined at 465 nm. The PAH
clearance (mL/kg/min) was calculated as follows:
PAH clearance~
PAHi
½PAH 
 
1
(1{Hct)
Where:
PAHi=PAH infusion rate (mg?kg
21?min
21)
[PAH]=arterial plasma PAH concentration (mg/ml)
Hct=hematocrit ratio
Microsphere Isolation
Microspheres were utilized to measure the effect of inflamma-
tion on tissue blood flow under basal conditions. Mice were fasted
at t=2300 min (,7:30 am) and at t=2240 min they received a
bolus of either vehicle or high-dose LPS. At t=120 min (6 h
following bolus), mice were injected with 50 mL of microspheres
(Dye-Trak VII, Triton Technology, INC, San Diego, CA)
followed by 50 mL saline into the carotid artery. Mice were
anesthetized and the tissues were excised. The tissues were
digested overnight in 1 M KOH at 60uC. Following vortex and
centrifugation, the pellet containing the microspheres was re-
suspended with TritonX-100 and centrifuged. The pellet was re-
suspended in ethanol containing 0.2% (v/v) HCL, centrifuged and
re-suspended in ethanol. The resulting product was centrifuged
and a small amount of ethanol was left on the pellet and allowed to
evaporate at room temperature overnight. Cellosolve acetate
(250 mL) was added to the microsphere:ethanol solution to elute
the fluorescent dye from the microspheres. The absorbance was
determined at 440 and 672 nm. Tissue blood flow was calculated
as the product of the ratio of microspheres in a tissue relative to
microspheres in both kidneys and PAH clearance (ml/min)
divided by tissue weight (ml?g tissue
21?min
21).
Echocardiography
Transthoracic echocardiography was performed using a system
(Sonos 5500, Agilent, Andover, MA) with a 15-MHz high
frequency linear transducer at a frame rate of 100 frames/sec.
All images were acquired at a depth setting of 20 mm. Images
were acquired at two time points: t=0 min, which represents the
time immediately prior to an injection of LPS and at t=360 min
(6 h following the bolus). The mouse was picked up at the nape of
its neck and an ultrasound-coupling gel was applied to the
precordium, with the ultrasound probe. Two-dimensional targeted
M-mode echocardiographic images were obtained at the level of
the papillary muscles from the parasternal short-axis vies and
Figure 1. Protocol used during the hyperinsulinemic-euglycemic clamp. On the day of the in vivo metabolic experiments, chronically
catheterized conscious mice were placed on a 5 h fast (t=2300 min). A bolus of VEH, low- or high-dose LPS was injected at t=2240 min. At
t=2120 a primed continuous tracer infusion was begun. At t=0 an infusion of insulin and glucose or vehicle (i.e. saline) was initiated. After 100 min,
2-deoxy glucose was injected and mice were sacrificed after 25 min.
doi:10.1371/journal.pone.0030160.g001
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measurements of heart rate. All other measurements were made
on screen using the digitally recorded signals. These measurements
were used to calculate stroke volume and cardiac output [14,15]:
(L)~
7
2:4zLVIDd

|LVIDd
3
(L)~
7
2:4zLVIDs

|LVIDs
3
Cardiac Output (mL:G{1:min
{1
)~
(Stroke Volume|Heart Rate)
Body Weight (g)|1000
Where LVIDd and LVIDs are left ventricular internal dimensions
during diastole and systole, respectively.
Indirect Calorimetry
Oxygen consumption (VO2) was measured by an Oxymax indirect
calorimeter (Columbus Instruments, Columbus, OH). Air flow was
set at 0.60 l/min and mice were housed individually for 1 day before
entering the calorimeter. After a 1 h adaptation to the metabolic
chamber, VO2 was measured in individual mice for 1 min at 15-min
intervals for a total of 48 h under a consistent environmental
temperature (22uC). Following 48 h of baseline measurements, food
was removed and intraperitoneal injections of vehicle (n=5), low-
(n=6) or high-dose (n=9) LPS were administered. VO2 was
calculated for 8 h following the IP injections. VO2 is expressed as
the volume of O2 consumed per kilogram body weight per hour.
Western Blots
Protein from skeletal muscle and liver was extracted with a
buffer containing 50 mM Tris, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% Triton X-100 at pH 7.5. Before using 1 mM DTT,
1 mM PMSF (dissolved in ethanol), 5 ug/mL protease inhibitor
cocktail, 10 ug/mL trypsin inhibitor, 50 mM NaF, and 5 mM
NaPP were added to the buffer. The tissues were homogenized on
ice and centrifuged for 20 min in the cold room. The protein
extract was collected and stored at 280uC until used. Protein
extracts (20 mg) were combined with NuPage LDS sample loading
buffer (4X), NuPage reducing agent (10X) (Invitrogen, Carlsbad,
CA), and distilled water up to 25 mL. This was placed in a 75uC
water bath for 10 min, and size-fractionated by electrophoresis on
10% SDS-polyacrylamide gel (Invitrogen, Carlsbad, CA). Proteins
were transferred from the gel to a PVDF transfer membrane by
electroblotting. Membranes were incubated at room temperature
with 5% nonfat dried milk, in Tris-buffered saline-Tween (TBS-T)
(Sigma, St. Louis, MO) for 2 h, washed 3X for 5–10 min in TBS-
T, and then incubated overnight at 4uC with mouse anti-pAkt
(Ser
473) antibody (1:1,000), mouse anti-Akt antibody (1:500),
mouse anti-pGSK (Ser
9), mouse anti-GSK antibody (1:1,000)
mouse anti-IRS-1 (1:1000), mouse anti-pIRS-1 (Tyr
895), or mouse
anti-pIRS-1(Ser
307) (all antibodies purchased at Cell Signaling
Technology, Danvers, MA). After incubation, samples were
washed 3X for 5–10 min in TBS-T, incubated with peroxidase-
conjugated secondary antibody, and analyzed using enhanced
chemiluminescence (GE Healthcare, Piscataway, NJ).
Real Time PCR
Total mRNA was extracted from the skeletal muscle and liver
using the RNeasy fibrous tissue kit (Qiagen Sciences, German-
town, MD). cDNA was synthesized from 2.5 mg RNA with the
SuperScript III first-strand synthesis system first-strand cDNA
synthesis kit (Invitrogen, Carlsbad, CA). PCR amplification
reactions were performed in triplicate using the ABI detection
system (Applied Biosystems, Foster City, CA) and the DDCT
method was used to quantify mRNA levels. Gene expression was
normalized to 18S rRNA levels. PCR amplification to detect
inducible NOS (iNOS) and the housekeeping 18S rRNA was
performed with TaqMan gene expression assays (proprietary
primers and probes designed and synthesized by Applied
Biosystems). Data are presented as fold increase relative to
measurements in vehicle-treated mice.
Data Analysis
All data was analyzed using SigmaPlot 12.0 (Aspire Software
International, Ashburn, VA). Data are presented as the mean 6
SEM. Differences between groups were determined by ANOVA.
The Holm-Sidak post hoc test was used to identify differences
between specific groups. Paired comparisons were performed with
the two-tailed Student’s t test. The significance level was set at
P,0.05.
Results
LPS Increases Plasma Cytokine Levels
Arterial plasma TNF-a, IL-6, IL-1b, and IL-10 levels were
measured at two time points (4-, and 6-h post-vehicle or LPS
injection), which represent the time points at the beginning and
end of the hyperinsulinemic-euglycemic clamp. Cytokine levels
were equal in the three groups during the basal period (data not
shown). At 4 h after LPS injection, the mice that received low-dose
LPS had significantly higher TNF- a (3-fold), IL-6 (3-fold), IL-1b
(3-fold), and IL-10 (5-fold) above mice that received vehicle
(Figure 1). The mice that received high-dose LPS also had
significantly higher levels of TNF-a (7-fold), IL-6 (4-fold), IL-1b (7-
fold), and IL-10 (6-fold) over vehicle-treated animals. Only IL-1b
levels was significantly increased in high-dose LPS compared to
mice that received low-dose LPS (2-fold). At 6 h post-LPS
injection only TNF-a and IL-6 remained significantly increased
in mice having received low dose LPS compared to vehicle-treated
mice (3- and 6-fold respectively). In mice that received high-dose
LPS significant increases in TNF-a, IL-6, IL-1b, and IL-10 still
remained 6 h post injection compared to vehicle-treated animals
(4-, 12-, 8-, and 2-fold respectively) and in IL-6, IL-1b and IL-10
compared to low-dose LPS treated animals (2-, 4- and 2-fold
respectively; Figure 2).
LPS Inhibits Insulin-Stimulated Muscle Glucose Uptake
There was no significant difference in the body weight (grams)
between mice that received vehicle, low-, or high-dose LPS
(25.360.8, 26.660.8, and 25.360.7, respectively). During the
saline infusion, there was no significant difference in fasting arterial
glucose concentrations between mice that received vehicle, low-, or
high-dose LPS (Figure 3A). However, insulin levels (ng/mL) were
significantly lower 4-h post injection (t=0 min; 0.5160.10 vs.
0.1760.01) and 6-h post injection (t=125 min; 0.4760.05 vs.
0.2260.04) with high-dose LPS administration, while there was an
increase with low-dose LPS administration at t=0 min (0.5160.10
vs. 0.8860.07) and t=125 min (0.4760.05 vs. 1.1660.22). Basal
endogenous glucose production (mg?kg
21?min
21) was decreased in
mice that received both low- and high-dose LPS compared to
vehicle treated animals (1061.9, 7.461.2, and 6.360.9; vehicle,
low-dose, and high-dose LPS, respectively). Basal tissue glucose
uptake was also assessed in these mice. Basal tissue glucose uptake
LPS and Insulin Resistance
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was assessed except for the soleus. The response in the low-dose
group was highly variable which prevented us from detecting a
decrease in basal tissue glucose uptake (Figure 3B).
Insulin action was assessed in mice that received vehicle, low-
dose, or high-dose LPS under hyperinsulinemic-euglycemic clamp
conditions (Table 1). Because LPS decreases insulin clearance, the
insulin infusion rates were varied between the three groups to
match insulin concentrations. While glucose levels were main-
tained at ,120 mg/dl between all groups, there was a significant
difference in the glucose infusion rate (GIR; mgNkg
21Nmin
21)
necessary to maintain euglycemia between the mice that received
vehicle and mice that received low- and high-dose LPS (54.260.5
vs. 38.661.1 vs. 35.460.6; Figure 4A and 4B). Endogenous
glucose production was below zero in all groups indicating
complete suppression of liver glucose production by insulin. Low-
dose LPS markedly inhibited Rg in the gastrocnemius and SVL
muscles with no significant difference in any other tissues
measured compared to vehicle. High-dose LPS inhibited Rg in
all tissues measured (Figure 4C). However, when Rg was
compared to the fold-change over basal, low-dose LPS did not
lead to a significant decrease in the fold increase in glucose uptake
in any of the tissues measured, while mice that received high-dose
LPS, still had a significant decrease in the fold increase in glucose
uptake in the SVL and gastrocnemius muscles when compared to
vehicle (Figure 4D).
LPS Does Not Decrease Insulin Signaling
We assessed the effects of high-dose LPS treatment on insulin
signaling through the PI3 kinase pathway in the gastrocnemius
muscle by measuring insulin-mediated phosphorylation of Akt, a
key protein involved in insulin-stimulated MGU. When we
compared levels of pAkt (Ser
473) between control and LPS-treated
mice from tissues obtained at the end of the clamp, we found there
was no significant difference between the two groups (Figure 5A).
Similar results were seen for phosphorylation of the downstream
protein GSK (Figure 5B).To determine if LPS altered the
phosphorylation of substrates in the PI3 kinase pathway acutely,
4 h after LPS or vehicle treatment mice received a bolus of insulin
(10 U/kg body weight) and were sacrificed 10 min later. There
was no significant difference in the acute phosphorylation of IRS-1
or Akt signaling between the vehicle- and LPS-treated mice
(Figure 5C and 5D).
LPS Increases iNOS Expression in Muscle
We examined the effect of LPS administration on the expression
of inducible nitric oxide synthase (iNOS) in the skeletal muscle
from vehicle- and LPS-treated mice. LPS significantly increased
the expression of iNOS mRNA to a similar extent in the muscle in
both low- and high-dose LPS treated mice compared to vehicle
controls (Figure 6).
High-Dose LPS Treatment Decreases Muscle Blood Flow
Mean arterial blood pressure (mmHg) was unchanged in vehicle
treated mice. High-dose, but not low-dose, LPS lead to a
significant reduction in mean arterial blood pressure (115.865.3
vs. 96.665.3 [vehicle]; 119.263.9 vs. 86.563.9 [low-dose LPS],
123.763.2 vs. 77.463.2 [high-dose LPS], 2240 min vs. 0 min,
respectively). We next determined if high-dose LPS treatment
caused a similar reduction in blood flow. High-dose LPS treatment
led to a ,65% decrease in renal blood flow compared to vehicle
treated mice. This also resulted in ,65% decrease in muscle blood
Figure 2. Plasma cytokine levels following vehicle and LPS treatment. Plasma concentration of tumor necrosis factor-alpha (TNF; Panel A),
interleukin-1b (IL-1; Panel B), interleukin-6 (IL-6; Panel C) and interleukin-10 (Panel D; IL-10) 4- and 6-hours following vehicle (VEH), low-dose LPS (LD
LPS; 1 mg/gBW), and high-dose LPS (HD LPS; 10 mg/gBW) treatment in chronically catheterized conscious C57/Bl6J mice, Data are expressed as
mean6SEM. * p,0.05 vs. VEH, # p,0.05 vs. LD LPS.
doi:10.1371/journal.pone.0030160.g002
LPS and Insulin Resistance
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between the right and left kidney.
High-Dose LPS Impairs Cardiac Function
The effect of LPS-treatment on cardiovascular parameters and
whole body oxygen consumption (VO2) was examined. There
were no significant differences in stroke volume, heart rate, and
cardiac output in vehicle and low-dose LPS treated mice 6 h after
treatment. VO2 was not decreased in the low-dose LPS treated
mice compared to vehicle. However, the administration of high-
dose LPS led to a ,30% decrease in heart rate, ,30% decrease in
stroke volume, a ,50% decrease in cardiac output, and a ,50%
decrease in VO2 (Table 3).
Discussion
Skeletal muscle represents an important site for insulin-
stimulated glucose disposal. It is well known that insulin-stimulated
muscle glucose uptake is impaired in the presence of inflammatory
mediators. While it has been suggested from in vitro studies that the
underlying factors leading to this impairment is defective insulin
signaling, the mechanism in vivo remains to be clearly elucidated
[16,17]. The aim of the present study was to use a conscious
mouse model to test the hypothesis that there was a significant
vascular component to impaired insulin action in vivo resulting
from a LPS challenge. Our findings indicate that the inflammatory
stress induced by LPS in the mouse impairs MGU in vivo without
affecting insulin signaling. The impairment in MGU was
associated with decreases in muscle blood flow, suggesting that
alterations in muscle glucose delivery play a critical role in insulin
resistance when the cardiovascular system is altered.
Hyperinsulinemic-euglycemic clamps in chronically catheter-
ized conscious mice were used to determine insulin-stimulated
glucose uptake. In initial studies vehicle and high-dose LPS treated
mice were both infused with 4 mU?kg
21?min
21 of insulin during
the clamp. There was no difference in glucose requirements
between the groups. However, arterial insulin was two-fold higher
in mice that received LPS (5.0 vs. 2.5 ng/ml; LPS vs. vehicle)
implying that LPS impaired insulin clearance. In subsequent
studies the insulin infusion rate was reduced to 2.5 mU?kg
21?-
min
21 in an attempt to match circulating insulin levels in LPS
treated mice to those having received vehicle. Although insulin
levels remained somewhat higher, glucose requirements were
reduced by 35% and there was a significant decrease in glucose
uptake in multiple muscles. When the dose of LPS was decreased
to 1 mg/kg impairments in insulin-stimulated MGU were not as
robust. These results are consistent with findings in a variety of
species [18,19,20]. Our results suggest that decreased insulin
clearance by LPS may serve to normalize insulin-stimulated
glucose uptake. A recent study Park et al. found that during a
hyperinsulinemic-euglycemic clamp LPS did not affect insulin
action in vivo [10]. In the presence of LPS, there was either an
increase or no difference in the glucose infusion rate versus
animals that received saline. Similar results were seen when they
examined whole-body glucose disposal. They found that while
LPS lead to a decrease in hepatic glucose production, muscle
glucose uptake was unaltered. Interestingly insulin concentrations
were not reported [10]. Pilon et al. did observe a decrease in whole
body glucose uptake during the hyperinsulinemic-euglycemic
clamp 6 h after administering LPS. In contrast to our study,
insulin-stimulated glucose uptake by the soleus (other tissues were
not evaluated) was markedly decreased however they utilized a
higher dose of LPS than our high dose group (20 mg/kg). Like
Park et al., they also did not report insulin concentrations during
the clamp [10,16]. We found that LPS impaired insulin clearance
therefore the insulin infusion rate during the clamp was decreased
to maintain similar arterial insulin concentrations between groups.
Thus, it is likely that in their study impairments in insulin
clearance and the consequent increase in arterial insulin
Figure 3. Basal glucose concentrations and tissue glucose uptake following vehicle and LPS treatment. Basal arterial glucose
concentrations (Panel A) and tissue glucose uptake (Panel B) in chronically catheterized 5-hour fasted C57/BL6j mice that received vehicle (VEH), low-
dose LPS (LD LPS; 1 mg/gBW), or high-dose LPS (HD LPS; 10 mg/gBW). Data are expressed as mean6SEM. * p,0.05 vs. VEH, # p,0.05 vs. LD LPS.
doi:10.1371/journal.pone.0030160.g003
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impairment in insulin stimulated tissue glucose uptake.
Defects in insulin signaling through the PI3-kinase pathway in
the muscle during a LPS challenge do not contribute to impaired
glucose uptake. Consistent with our previous work LPS treatment
increases the plasma levels of inflammatory cytokines [21]. de
Alvaro et al. found that in cultured rat skeletal muscle cells TNF-a
lead to a decrease in insulin signaling through the IR/IRS-1/AKT
pathway [22]. Impairments in insulin signaling are mediated in
part by increased cytokines and subsequent NFkB pathway
activation that occurs in response to LPS [23,24]. We observed
an increased expression of iNOS in muscle, which is consistent
with recent reports [16]. Despite the robust activation of the
inflammatory response, Akt phosphorylation in gastrocnemius
muscle at the end of the clamp was unaltered by LPS. Pilon et al.
observed a decrease in insulin stimulated IRS-1 associated PI 3-
kinase activity in soleus (other muscles were not examined)
obtained from control and LPS treated mice (6 h after LPS
Figure 4. Glucose concentrations and insulin-stimulated tissue glucose uptake following vehicle and LPS treatment. Arterial glucose
concentrations (Panel A); glucose infusion rate (GIR; Panel B) and tissue (soleus, gastrocnemius, superficial vastus lateralis (SVL), heart, and brain)
glucose uptake (Panel C), and fold-change from basal of insulin-stimulated glucose uptake (Panel D) during a hyperinsulinemic-euglycemic clamp in
chronically catheterized 5-hour fasted C57/BL6j mice that received vehicle (VEH), low-dose LPS (LD LPS; 1 mg/gBW), or high-dose LPS (HD LPS; 10 mg/
gBW),. Data are expressed as mean6SEM. * p,0.05 vs. VEH, # p,0.05 vs. LD LPS.
doi:10.1371/journal.pone.0030160.g004
Table 1. Arterial plasma insulin levels after a
hyperinsulinemic-euglycemic clamp following vehicle or LPS
treatment.
Time (min) 0 125
Insulin (ng/ml)
Vehicle 0.3360.09 2.5460.19
Low-Dose LPS 0.8860.07 3.0460.30
High-Dose LPS 0.3260.04 3.7360.25
Arterial plasma insulin levels in response to vehicle, low- (1 mg/gBW), or high-
(10 mg/gBW) dose LPS in chronically catheterized conscious mice during the
basal period (0 min) and 125 min after initiation of a hyperinsulinemic-
euglycemic clamp. Data are expressed as mean6SEM.
doi:10.1371/journal.pone.0030160.t001
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473; Panel A) and GSK phosphorylation (Panel B) in
the gastrocnemius muscle of C57/BL6j mice that received vehicle (VEH) or high-dose LPS (HD LPS; 10 mg/gBW) after a hyperinsulinemic-euglycemic
clamp. Akt phosphorylation (Ser
473; Panel C) and phosphorylation of IRS-1 (Tyr
895 and Ser
307; Panel D) in the gastrocnemius muscle of C57/BL6j mice
after an acute bolus of saline or insulin. Data are expressed as mean6SEM. *p,0.05.
doi:10.1371/journal.pone.0030160.g005
Figure 6. Effect of vehicle and LPS treatment on the expression
of iNOS. Expression of inducible nitric oxide synthase (iNOS) mRNA in
the gastrocnemius muscle of C57/BL6j mice that received vehicle, low-
dose LPS (1 mg/gBW), or high-dose LPS (10 mg/gBW) after a hyperin-
sulinemic-euglycemic clamp. Data are expressed as mean6SEM.
*p,0.05.
doi:10.1371/journal.pone.0030160.g006
Table 2. Renal and tissue blood flow following vehicle or LPS
treatment.
VEH LPS
Renal blood flow (ml?kg BW
21 min
21)
363694 12668*
Tissue blood flow (ul?g tissue
21?min
21)
Soleus 680563440 22196659*
Gastrocnemius 5836134 194629*
SVL 9766183 359688*
Heart 13896362 416653*
Renal and muscle (soleus, gastrocnemius, superficial vastus lateralis, and heart)
blood flow were compared in mice that received either vehicle (VEH) or high-
(10 mg/gBW) dose LPS. Data are expressed as mean6SEM.
*p,0.05.
doi:10.1371/journal.pone.0030160.t002
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vascular-dependent effects of insulin are absent. While in vitro
models can unmask insulin signaling defects, it prevents detection
of any vascular dependent alterations in insulin action. An
additional consideration is that the impairment in insulin signaling
may be dependent upon the time of exposure to the inflammatory
environment, the dose of LPS administered, and the specific
muscle group examined. Pilon examined insulin action utilizing a
2-fold higher dose of LPS than our high-dose group [16]. To assess
whether the peak phosphorylation events were missed during the
120 min clamp study, Akt phosphorylation was examined
10 minutes following a bolus of insulin. This experiment
confirmed the findings from the insulin clamp studies; LPS
administration in vivo did not blunt insulin signaling in the muscle.
Since Akt phosphorylation can be influenced by multiple events,
we next looked upstream in the insulin signaling pathway at IRS-1
phosphorylation. We found that LPS administration did not blunt
tyrosine phosphorylation nor did it increase serine phosphoryla-
tion of IRS-1 compared to vehicle treatment. These data suggest
that there is dissociation between insulin-stimulated muscle glucose
uptake and phosphorylation of key proteins in the PI3 kinase
insulin signaling pathway. This strongly suggests that other factors
can limit muscle glucose uptake in vivo.
Consistent with the insulin signaling data we found that despite
the absolute decrease in MGU the fold increase above basal MGU
was unaltered in several tissues. Insulin-stimulated MGU increased
,10 fold above vehicle infused mice irrespective of whether they
are given LPS. This suggests that the tissues were very responsive
to insulin but that other factors such as a decrease in metabolic
demand or vascular delivery of glucose limited the absolute
magnitude of glucose uptake. Cardiac output following low-dose
LPS was not significantly altered. However, we found that high-
dose LPS significantly decreased cardiac output by ,50% and
mean arterial blood pressure fell by ,50%. In conjunction with
these results, we found that VO2 was significantly decreased with
high-dose LPS (,50%) while low-dose LPS (,20%) did not
significantly decrease metabolic demand (i.e. VO2). A correlation
between metabolic demand and insulin stimulated glucose uptake
is well established as increasing metabolic demand can compensate
for underlying insulin resistance [25,26,27]. This may in fact
explain why in humans it has been reported that during
endotoxemia insulin can initially improve insulin action [28].
The low dose of LPS used in human studies induced modest
cardiovascular alterations (tachycardia and mild hypotension). In
contrast to the mouse in both the human and pig the dose of LPS
used caused hyperthermia, presumably increasing the metabolic
rate and limiting cardiovascular disturbances. Therefore depend-
ing on the species, the duration of exposure to, and the dose of
LPS used, among other factors such as the metabolic rate and
associated cardiovascular events, may offset any negative effects of
LPS on tissue glucose uptake. Thus, the combined decrease in
tissue blood flow and VO2 following LPS may explain the
accompanying impairment in MGU seen in our mouse model.
Low dose LPS had limited alterations in cardiac output yet they
were insulin resistant. This could be due to subtle changes in tissue
perfusion that combine with other defects downstream of AKT
signaling (e.g. glucose transport or phosphorylation). Our data
suggest that the accompanying cardiovascular events should be
considered when interpreting the impact of LPS in vivo.
Previous studies have shown that increased blood flow leads to
increased glucose uptake provided the muscle membrane is
sufficiently permeable to glucose, such as it is during insulin
stimulation [29,30]. The impairment in MGU following LPS
administration could be due to the combined effects of reduced
tissue blood flow and/or extraction of glucose. Using PAH and
microspheres to measure tissue blood flow we found that after
high-dose LPS muscle blood flow was significantly impaired
compared to vehicle-treated animals. This would decrease muscle
glucose delivery and in the absence of a compensatory increase in
fractional glucose extraction, MGU. Blood flow and glucose
uptake decreased proportionally in both the SVL and gastrocne-
mius muscle (,69%), which suggests that fractional glucose
extraction was unaltered. In contrast, blood flow to the heart and
soleus decreased to a greater extent (,70% and 65%, respectively)
than the fall in glucose uptake (,50% and 25%, respectively). This
suggests that these tissues had a compensatory increase in
fractional extraction of glucose and were able to minimize the
decrease in tissue glucose uptake. As fat is the preferred substrate
in these tissues they may switch to glucose utilization as the
preferred substrate in low flow states. Indeed, studies by Petersen et
al. demonstrated that the extracellular barrier to glucose uptake
was lower in Type I muscle fibers [31]. Thus tissues with greater
oxidative capacity and capillary densities (heart and soleus) have a
greater ability to extract glucose in setting of insulin resistance and
low flow states.
An inflammatory state can lead to decreased microcirculatory
flow velocity and the density of perfused capillaries in rat models
both of which are important factors in determining MGU [32,33].
Our data suggests that high-dose LPS decreases blood flow to the
muscle which subsequently impairs MGU. This is consistent with
data that there is a redistribution of blood flow during
inflammatory stress [34]. Unlike glucose, decreased muscle insulin
delivery would not necessarily result in decreased insulin signaling
because insulin is not consumed by the muscle. Therefore the
concentration of insulin presented to muscle cells would be
Table 3. Cardiovascular parameters following vehicle or LPS
treatment.
Time (h) 0 6
Stroke Volume (uL)
Vehicle 36634 8 67
Low Dose LPS 63695 1 66
High Dose LPS 48623 2 62{
Heart Rate (bpm)
Vehicle 720614 648621{
Low Dose LPS 667646 6 7 628
High Dose LPS 678619 450649{*#
Cardiac Output (ml?g
21?min
21)
Vehicle 0.6760.07 0.8260.16
Low Dose LPS 1.2160.19 0.9960.12
High Dose LPS 0.9160.17 0.4260.12{*#
VO2 (ml?kg
21?h
21)
Vehicle 31876161 30446249
Low Dose LPS 33466116 26366293{
High Dose LPS 3212661 16536218{*#
Comparison of stroke volume, heart rate, cardiac output, and oxygen
consumption (VO2) in mice at baseline (t=0) and 6 h after receiving vehicle,
low- (1 mg/gBW), or high- (10 mg/gBW) dose LPS. Data are expressed as
mean6SEM.
{p,0.05 vs. baseline;
*p,0.05 vs. VEH at 6 h;
#p,0.05 vs. low-dose LPS at 6 h.
doi:10.1371/journal.pone.0030160.t003
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difference in IRS and Akt phosphorylation between vehicle- and
LPS-treated mice indicates a disassociation of insulin-stimulated
glucose uptake and insulin signaling though the PI3 kinase
pathway in muscle. Similar results in insulin signaling were
observed by Orellana et al. in the neonatal pig [35]. The
impairment in tissue blood flow following LPS administration is
consistent with studies suggesting that skeletal muscle perfusion
could act as an independent determinant of insulin stimulated
glucose uptake [3,29,36]. The brain is not an insulin responsive
tissue therefore during a hyperinsulinemic-euglycemic clamp we
would not expect a decrease in the glucose uptake. Therefore a fall
in brain glucose uptake under these conditions is also consistent
with a decrease in tissue blood flow. Pilon et al. observed that mice
lacking iNOS are protected from LPS-induced insulin resistance
due to diminished nitrosylation of IRS-1 in the soleus muscle [16].
However, an equally plausible explanation is that these mice are
protected from the hypotension and the decrease in tissue
perfusion that accompanies the excess nitric oxide generation
from LPS [37,38].
In summary, this study provides evidence that an LPS challenge
that impairs cardiovascular function significantly impairs MGU in
mice but does not affect the stimulation of insulin signaling in vivo
despite the release of inflammatory cytokines. Thus impairments
in effective tissue perfusion can contribute to the decreased glucose
uptake observed during endotoxemia.
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